Molecular Partners Raises $45 Million
Molecular Partners AG, a Swiss developer of DARPins as protein therapeutics, has raised CHF40 million (US$45m) in Series B funding. Essex Woodlands Health Ventures led the round, and was joined by return backers Ventures, Johnson & Johnson Development Corp., BB Biotech Ventures and Endeavour. The company has now raised CHF64.5 million.
15 December 2009•2 mins read
